Latest Asx Listings News

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals is seeking a re-examination of the European Medicines Agency’s refusal to approve trofinetide for Rett syndrome, aiming to overturn the setback and bring the treatment to European patients.

Oldfields Holdings Limited remains suspended from ASX trading following its failure to lodge critical half-year financial reports after announcing a capital raising.

Rincon Resources has successfully raised $3.1 million to fund an expanded drilling campaign at its promising Telfer South Gold-Copper Project, following the discovery of a significantly larger mineralised zone at the Hasties Prospect.

Australian Bond Exchange Holdings has completed a $0.98 million placement and is proposing attaching options to raise additional funds, pending shareholder approval.

Horizon Oil has made a strategic move to acquire the remaining shares of Cue Energy Resources with an offer valuing Cue shares at approximately 14.3 cents each, representing a notable premium. This bid aims to create a larger, more diversified oil and gas entity with potential annual synergies of up to A$2 million.

Nexion Group Ltd reports a striking turnaround to a $6.3 million net profit in H1 2026, driven by gains from subsidiary sales, while continuing operations still face losses amid efforts to regain ASX trading status.

Freedom Care Group Holdings outlines a strategic recovery plan following the suspension of its securities and liquidation of its main operating subsidiary, aiming to restore shareholder value and regain ASX listing.

KneoMedia Limited reported a half-year loss of $1.02 million for H1 FY26, impacted by delayed payments from New York City amid a mayoral transition. The company is preparing for ASX reinstatement and a $3 million capital raise to support growth.

Vinyl Group Ltd has reported a robust 49% increase in revenue for the first half of FY26, alongside a significant reduction in net loss, driven by strategic acquisitions and AI integration.

Atomos Limited has reported a profitable first half of FY26 with revenue up 28%, driven by strong sales and cost discipline. The company reaffirms its full-year guidance, anticipating further growth and positive cash flow in the second half.

Clarity Pharmaceuticals has reported a steep 136% increase in its half-year loss to $55.6 million, alongside the closure of its European subsidiary, signaling a challenging period for the ASX-listed biotech.

6K Additive, a US-based metal powder innovator, reports a 3.85% revenue dip to US$17.7 million and narrows net loss to US$17.9 million in its first ASX-listed year. The company plans a fivefold capacity expansion backed by significant government grants and a US$27.4 million loan.